Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 5 sources · 22 days · First seen · Last updated
DocMorris financial restructuring and market performance
Overview
DocMorris AG has undertaken strategic financial restructuring and improved its market outlook. In early September 2026, the company completed a private placement of approximately CHF 100 million in convertible bonds due in 2031. This move was intended to extend the company’s financing horizon, reduce its coupon rate from 3.0% to 1.5%, and proactively manage share dilution.
By late September 2026, DocMorris shares reached a 52-week high of 13.18 CHF following upwardly adjusted financial forecasts. Management increased external revenue growth expectations to between 9 and 13 percent and narrowed the projected adjusted EBITDA loss range. The company is currently targeting an operational turning point, aiming for adjusted EBITDA break-even in the second half of the fiscal year and cash flow break-even by 2027.
Entities
Timeline
-
[BUSINESS] 3 sourcesDocMorris shares reach 52-week high amid improved forecasts
DocMorris shares hit a 52-week high of 13.18 CHF as the company raised its growth forecasts and targets an EBITDA break-even in the second half of the fiscal year.
-
[BUSINESS] 2 sourcesDocMorris completes CHF 100 million convertible bond placement
DocMorris AG has completed a CHF 100 million private placement of convertible bonds due in 2031, extending its financing maturity and reducing its coupon rate to 1.5%.
Sources
biotech-investments.com · cash.ch · finanzen.ch · finanznachrichten.de · sharedeals.de